Background

Etomidate is an imidazole-based intravenous hypnotic first introduced into clinical practice in the 1970s, widely recognised for its rapid onset of action and relatively stable cardiovascular profile [1,2]. These properties have historically made it valuable for anaesthesia induction in patients with compromised haemodynamic status. However, etomidate is also associated with several clinically significant adverse effects, most notably adrenocortical suppression due to inhibition of steroidogenic enzymes [3]. Over the past two decades, renewed scientific interest has focused on the development of etomidate analogues which are structurally modified derivatives designed to retain favorable hypnotic and haemodynamic properties while reducing endocrine toxicity and other adverse effects [4]. Several of these compounds have progressed through pre‑clinical development and early human trials [5]. In parallel with legitimate pharmaceutical research, non‑medical or misrepresented use of etomidate and related substances has emerged as a concern, particularly where these compounds are detected outside authorised medical settings [1]. 

Definition and description

Etomidate analogues are synthetic compounds chemically related to etomidate, typically modified at the ester side chain or heterocyclic ring [5,6]. Most etomidate analogues act as positive allosteric modulators of the γ‑aminobutyric acid type A (GABA_A) receptor, similar to etomidate itself, with selectivity for specific receptor subunits [2]. From an early warning perspective, etomidate analogues may appear in non‑medical contexts, including as substances misrepresented as other sedatives, analgesics, or “research chemicals” [1].



Figure 1: Core structure of etomidate and representative analogues.

The conserved etomidate scaffold is shown in Figure 1 with variable substitution sites (R₁–R₄ on the aromatic ring and R₅ on the ester moiety), highlighting how systematic modifications, particularly at R₅ and on the phenyl ring, have generated analogues with altered pharmacokinetics, metabolic lability, and adrenocortical effects. Listed examples include classical alkyl esters (e.g., metomidate, propoxate), branched and fluorinated derivatives, soft‑drug designs (e.g., CPMM/ABP‑700), and ring‑substituted analogues developed to modulate GABAA_AA​ activity while reducing inhibition of adrenal steroidogenesis.

Commonly reported forms

From an early warning and laboratory monitoring perspective, etomidate analogues may be encountered in [1,5]:

• Pharmaceutical injectable solutions (legitimate clinical or diverted supply)
• Powders or crystalline solids
• Liquids, including solutions intended for injection or other administration routes
• Non‑medical preparations, including products misrepresented as sedatives, hypnotics, or “research chemicals”

Detection outside controlled medical use is of particular concern due to narrow safety margins, uncertainty regarding dose, and potential for misidentification.

Reported effects and toxicological considerations